Immobilized Human IL-31 Protein, His Tag at 1 μg/mL (100 μL/well) can bind Human IL-31 RA Protein, Fc Tag with EC50 of 0.11-0.15 μg/ ml.
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Interleukin-31, IL31 |
| Accession | Q6EBC2 |
| Amino Acid Sequence | Protein sequence (Q6EBC2, Ser24-Thr164, with N-His Tag) SHTLPVRLLRPSDDVQKIVEELQSLSKMLLKDVEEEKGVLVSQNYTLPCLSPDAQPPNNIHSPAIRAYLKTIRQLDNKSVIDEIIEHLDKLIFQDAPETNISVPTDTHECKRFILTISQQFSECMDLALKSLTSGAQQATT |
| Expression System | HEK293 |
| Molecular Weight | Predicted MW: 17.5 kDa Observed MW: 20 kDa |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <1EU/μg |
| Conjugation | Unconjugated |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4 with 3% trehalose. |
| Reconstitution | Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation. |
| Stability & Storage | 12 months from date of receipt, -20 to -70 °C as supplied. |
Background
Interleukin-31 (IL-31) is a novel cytokine belonging to the IL-6 family, primarily produced by activated T helper 2 (Th2) cells and mast cells. It signals through a heterodimeric receptor composed of IL-31 receptor A (IL-31RA) and oncostatin M receptor β (OSMRβ), which is expressed on various cell types including sensory neurons, keratinocytes, and immune cells. IL-31 is a key mediator of pruritus (itch) in inflammatory skin diseases such as atopic dermatitis, psoriasis, and allergic conditions. Its signaling pathway promotes itch sensation, disrupts epidermal barrier function, and drives immune responses, making it a significant therapeutic target for chronic pruritic disorders.
Picture
Picture
Bioactivity
SDS-PAGE
2μg(R: reducing conditions)
